Table 3.

Multivariate analyses of week 6 VTC values using the determined threshold, potential covariates, and week 30 FCP or week 30 CRP.

	CRP analysis group 1				FCP analysis group 1
	Individuals with Crohn’s disease		Individuals with ulcerative colitis		Individuals with Crohn’s disease
Variables	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Week 6 VTC threshold FCP: >43.15 μg/ml (CD) CRP: > 41.65 μg/ml (CD) >39.65 μg/ml (UC)	3.22 (1.32, 7.87)	0.010	4.03 (1.30, 12.52)	0.016	1.59 (0.54, 4.72)	0.400
Age (years)	0.98 (0.96, 1.01)	0.268	1.002 (0.98, 1.03)	0.858	1.01 (0.97, 1.05)	0.662
Sex (female vs male)	1.01 (0.44, 2.31)	0.983	0.69 (0.23, 2.02)	0.496	2.74 (0.94, 8.02)	0.065
Week 0 albumin (g/l)	0.97 (0.88, 1.06)	0.471	1.007 (0.92, 1.11)	0.880	1.24 (1.03, 1.49)	0.026
Disease duration (>2 years vs ≤2 years)	1.17 (0.43, 3.13)	0.760	0.82 (0.27, 2.46)	0.726	0.84 (0.26, 2.76)	0.773
Biologic treatment exposure (bio-naïve vs bio-exposed)	1.63 (0.69, 3.86)	0.266	1.15 (0.43, 3.09)	0.782	1.18 (0.40, 3.47)	0.761

CD, Crohn’s disease; CRP, C-reactive protein; FCP, faecal calprotectin; UC, ulcerative colitis; VTC, vedolizumab trough concentration.

Bold P values indicate statistical significance at P < 0.05.

Italicized variables are the reference for each analysis.